Antoine Boulanger | Senior Associate, Forbion

Antoine joined Forbion in March 2019 after receiving his Ph.D. in Molecular Medicine from Laval University in Canada. As a member of the investment team, he is involved in sourcing and evaluating new investment opportunities, as well as supporting portfolio companies as a board observer with Inversago Pharma, Azafaros, Rectify Pharma, Oxitope Pharma, Armgo Pharma and Dyne Therapeutics until their listing on NASDAQ in 2020 (DYN). Before joining Forbion, Antoine worked with the BDC Healthcare Venture Fund in Montreal, performed a fellowship with Forbion in Naarden and was involved in life sciences equity research. During his graduate studies, he contributed to the discovery of the RANK/RANKL/OPG molecular pathway in skeletal muscle, investigations leading altogether to the publication of a dozen of authored and co-authored scientific papers in the field of muscle physiology, neuromuscular diseases and muscular dystrophy.

Anne Marije van Harten | Analyst, Forbion

Prior to joining Forbion in 2022, Anne worked as a postdoctoral fellow at Thomas Jefferson University in Philadelphia. She obtained her own research funding for her pre-clinical research focused on a newly discovered essential gene for p53 mutant cancers, using targeted PROTAC molecules.In 2020 she received her PhD degree in cancer biology at the Amsterdam UMC / VU University in Amsterdam, where she studied several essential DNA replication proteins, G2/M cell cycle checkpoint proteins and apoptotic regulators as targets for cancer therapy. Several (collaborative) papers were published as a result of this work, including a review on the identification of new targeted therapies in head and neck cancer. Before starting as a postdoctoral fellow, Anne worked at the University of Pennsylvania in Philadelphia investigating DNA replication and DNA damage repair proteins in relation to replication stress in 2019.Anne also holds a MSc in Oncology and a BSc in Biomedical sciences, both from the VU University in Amsterdam.